ACUMIN   Version 3.0 
 19 November,  2018  
 
 
1  
A Phase IV  Open -Label Pharmacokinetic Study of Minocycline for Injection Following a Single 
Infusion in Critically -Ill Adults (ACUMIN)  
DMID Protocol Number:  16-0011 
 
DMID Funding Mechanism:  1UM1AI104681-01 
Pharmaceutical Support Provided by:   Rempex Pharmaceuticals, Inc., a wholly owned 
subsidiary of Melinta Therapeutics Inc.  
Other Identifying Numbers:  ARLG_MINO- Yr4 
IND Sponsor:   Division of Microbiology and Infectious Diseases  (DMID)  
Principal Investigator:  Richard Wunderink, MD 
ARLG Project Lead:   Zoë Sund  
DMID Clinical Project Manager :  Marina Lee, PhD   
DMID Medical Monitor:  Venus Shahamatdar, MD 
Version Number: 3.0 
19 November, 2018 
 
 
ACUMIN   Version 3.0 
 19 November,  2018  
 
 
2 STATEMENT OF COMPLIA NCE 
The study will be carried out in accordance with Good Clinical Practice (GCP) as required by the 
following (use applicable regulations depending on study location and sponsor requirements; 
samples follow) : 
• United States (US) Code of Federal Regulations (CFR ) applicable to clinical studies (45  CFR 
Part 46; 21 CFR Part 50, 21 CFR Part 56, and 21 CFR Part 312) 
• ICH E6; 62 Federal Register 25691 (1997)  
• Clinical Terms of Award  
 
All key personnel (all individuals responsible for the design and conduct of this stud y) have 
completed Human Subjects Protection Training. 
 
ACUMIN   Version 3.0 
 19 November,  2018  
 
 
3 SIGNATURE PAGE  
The signature below constitutes the approval of this protocol and the attachments, and provides 
the necessary assurances that this trial will be conducted according to all stipulations o f the 
protocol, including all statements regarding confidentiality, and according to local legal and 
regulatory requirements and applicable US federal regulations and ICH guidelines. 
 
Site Investigator:  
Signed:  Date:   
 Name  
Title 
   
ACUMIN   Version 3.0 
 19 November,  2018  
 
 
4 TABLE OF CONTENTS 
Statement of Compliance  ................................................................................................................ 2  
Signature Page ................................................................................................................................ 3  
Table of Contents ............................................................................................................................ 4  
List of Tables  .................................................................................................................................. 7  
List of Figure s ................................................................................................................................. 8  
List of Abbreviations ...................................................................................................................... 9  
Protocol Summary ........................................................................................................................ 12  
1 Key Roles  ................................................................................................................. 15  
2 Background Information and Scientific Rationale .................................................. 18  
2.1 Background Information ...........................................................................................18  
2.2 Rationale  ...................................................................................................................18  
2.3 Potential Risks and Benefits .....................................................................................19  
2.3.1  Potential Risks  ..............................................................................................19  
2.3.2  Known Potential Benefits .............................................................................21  
3 Objectives  ................................................................................................................ 22  
3.1 Study Objectives  .......................................................................................................22  
3.2 Study Outcome Measures .........................................................................................22  
3.2.1  Primary Outcome Measures  ..........................................................................22  
3.2.2  Exploratory Outcome Measures  ...................................................................23  
4 Study Design  ............................................................................................................ 24  
5 Study Enroll ment and Withdrawal .......................................................................... 25  
5.1 Subject Inclusion Criteria  .........................................................................................25  
5.2 Subject Exclusion Criteria  ........................................................................................25  
5.3 Treatment Assignment Procedures  ...........................................................................26  
5.3.1  Randomization Procedures ...........................................................................26  
5.3.2  Masking Procedures ......................................................................................26  
5.3.3  Reasons for Study Withdrawal .....................................................................26  
5.3.4  Handling of Withdrawals from the PK Analysis ..........................................27  
5.3.5  Termination of Study ....................................................................................27  
6 Study Intervention/Investigational Product ............................................................. 28  
6.1 Study Product Description ........................................................................................28  
6.1.1  Acquisition  ....................................................................................................28  
6.1.2  Form ulation, Packaging, and Labeling .........................................................28  
6.1.2.1  Minocin IV  ........................................................................................28  
6.1.2.2  Sterile Water for Injection (WFI), USP  ............................................29  
6.1.2.3  0.9% Sodium Chloride, USP (Normal Saline) .................................29  
ACUMIN   Version 3.0 
 19 November,  2018  
 
 
5 6.1.3  Product Storage and Stability........................................................................29  
6.1.3.1  Minocin IV  ........................................................................................29  
6.1.3.2  Sterile Water for Injection (WFI), USP  ............................................29  
6.1.3.3  0.9% Sodium Chloride, USP (Normal Saline) .................................29  
6.2 Dosage, Preparation and Administration of Study Intervention/Investigational 
Product ......................................................................................................................29  
6.3 Modification of Study Intervention/Investigational Product for a Subject ...............30  
6.4 Accountability Procedures for the Study Intervention/Investigational Product(s) ...30  
6.5 Assessment of Subject Compliance with Study Intervention/Investigational 
Product ......................................................................................................................30  
6.6 Concomitant Medications/Treatments  ......................................................................31  
7 Study Schedule ........................................................................................................ 32  
7.1 Screening (within 48 hours of enrollment) ...............................................................32  
7.2 Baseline (Dosing – 0 hrs) ..........................................................................................33  
7.3 1-24 hour Study Visits (post start of infusion)..........................................................33  
7.4 36 hour Study Visit (post start of infusion) ..............................................................34  
7.5 48 hour Time Point (Final Study Visit)  ....................................................................34  
7.6 SAE Follow-up Visit (as needed) .............................................................................35  
7.7 Early Termination Visit ............................................................................................35  
7.8 Unscheduled Visits ...................................................................................................35  
8 Study Procedures/Evaluations ................................................................................. 36  
8.1 Clinical Evaluations  ..................................................................................................36  
8.2 Laboratory Evaluations .............................................................................................37  
8.2.1  Clinical Laboratory Evaluations ...................................................................37  
8.2.2  Special Assays or Procedures  .......................................................................37  
8.2.3  Specimen Preparation, Handling, and Shipping ...........................................37  
8.2.3.1  Instructions for Specimen Preparation, Handling, and Storage ........37  
8.2.3.2  Specimen Shipment ..........................................................................38  
9 Assessment of Safety  ............................................................................................... 39  
9.1 Specification of Safety Parameters  ...........................................................................39  
9.2 Methods and Timing for Assessing, Recording, and Analyzing Safety 
Parameters  .................................................................................................................39  
9.2.1  Adverse Events  .............................................................................................39  
9.2.2  Serious Adverse Events ................................................................................39  
9.2.3  Expectedness  .................................................................................................41  
9.3 Reporting Procedures ................................................................................................41  
9.3.1  Serious Adverse Events ................................................................................41  
ACUMIN   Version 3.0 
 19 November,  2018  
 
 
6 9.3.2  Regulatory Reporting for Studies Conducted Under DMID-Sponsored 
IND ...............................................................................................................42  
9.3.3  Reporting of Pregnancy ................................................................................42  
9.4 Type and Duration of Follow-up of Subjects after Serious Adverse Events ............43  
9.5 Halting Rules  ............................................................................................................43  
9.6 Safety Oversight (SMC)  ...........................................................................................43  
10 Clinical Monitoring .................................................................................................. 44  
10.1  Site Monitoring Plan  .................................................................................................44  
11 Statistical Considerations  ......................................................................................... 45  
11.1  Study Hypotheses ......................................................................................................45  
11.2  Sample Size Considerations ......................................................................................46  
11.3  Planned Interim Analyses .........................................................................................46  
11.3.1  Safety Review  ...............................................................................................46  
11.4  Final Analysis Plan  ...................................................................................................46  
11.4.1  Physiological Measures  ................................................................................46  
11.4.2  Pharmacokinetic Analysis and Assessment of Pharmacokinetic-
Pharmacodynamic Target Attainment  ..........................................................46  
12 Source Documents and Access to Source Data/Documents  .................................... 48  
13 Quality Control and Quality Assurance ................................................................... 49  
14 Ethics/Protection of Human Subjects ...................................................................... 50  
14.1  Ethical Standard  ........................................................................................................50  
14.2  Institutional Review Board  .......................................................................................50  
14.3  Informed Consent Process ........................................................................................50  
14.4  Exclusion of Women, Minorities, and Children (Special Populations) ....................51  
14.5  Subject Confidentiality  .............................................................................................51  
14.6  Study Discontinuation ...............................................................................................51  
14.7  Future Use of Stored Specimens ...............................................................................51  
15 Data Handling and Record Keeping  ........................................................................ 52  
15.1  Data Management Responsibilities ...........................................................................52  
15.2  Data Capture Methods  ..............................................................................................52  
15.3  Types of Data  ............................................................................................................52  
15.4  Timing/Reports  .........................................................................................................53  
15.5  Study Records Retention ...........................................................................................53  
15.6  Protocol Deviations ...................................................................................................53  
16 Publication Policy  .................................................................................................... 54  
17 Literature References  ............................................................................................... 55  
Supplements/Appendices  .............................................................................................................. 56  
Appendix A: Schedule of Events .................................................................................................. 57  
ACUMIN   Version 3.0 
 19 November,  2018  
 
 
7 LIST OF TABLES  
Table 1: Schedule of Events ......................................................................................................... 57  
 
ACUMIN   Version 3.0 
 19 November,  2018  
 
 
8 LIST OF FIGURES  
Figure 1: ACUMIN Study Diagram  ............................................................................................. 14  
Figure 2: Structural Formula of Minocin IV................................................................................. 28  
 
  
 
  
 
ACUMIN   Version 3.0 
 19 November,  2018  
 
 
9 LIST OF ABBREVIATION S 
AE Adverse Event  
Alpha, α Level of significance or distribution -phase elimination rate constant  
ARLG  Antibacterial Resistance Leadership Group  
ALT  Alanine aminotransferase 
ARLG  Antibacterial Resistance Leadership Group  
AST  Aspartate aminotransferase 
AUC  Area under plasma drug concentration versus time curve ratio  
AUC 0-24 Area under the plasma drug concentration -time curve from 0 to 24 hours 
after a dose  
AUC 0-last Area under the plasma drug concentration -time curve from 0 to the time of 
the last quantifiable sample after a dose  
AUC 0-∞ Area under the plasma drug concentration -time curve from 0 to infinity 
after a dose  
BLQ  Below Limit of Quantita tion 
BPM  Beats per minute  
BUN  Blood urea nitrogen 
CFR  Code of Federal Regulations  
CI Confidence interval  
CL Clearance  
CLd Distribution clearance  
Cmax  Maximum plasma  drug concentration 
C24 Plasma drug concentration at 24-hours after a dose 
CROMS  Clinical Research Operational Management Support  
DHHS  Department of Health and Human Services  
DMID  Division of Microbiology and Infectious Diseases, NIAID, NIH, DHHS 
eCRF  Electronic Case Report Form  
ACUMIN   Version 3.0 
 19 November,  2018  
 
 
10 fAUC:MIC  Free-drug AUC:MIC ratio  
FDA  Food and Drug Administration  
FOCEI  First-order conditional estimation method with interaction  
FWA  Federalwide Assurance  
GCP  Good Clinical Practice  
hCG Human Chorionic Gonadotropin 
HCl Hydrogen chloride 
ICF Informed Consent Form 
ICH International Council for Harmonization  
ICMJE  International Committee of Medical Journal Editors 
ICU Intensive Care Unit  
IDES  Internet Data Entry System 
IH Intrac ranial hypertension 
IND Investigational New Drug Application  
IRB Institutional Review Board  
IV Intravenous 
LAR  Legally Authorized Representative 
LCE  Leukocyte esterase  
LC-MS Liquid chromatography assay with mass spectrophotometry detection 
LLOQ  Lower Limit of Quantification  
MDR  Multiple Drug Resistant  
MIC  Minimum Inhibitory Concentration  
mg Milligrams  
mL Milliliters  
MOP  Manual of Procedures 
NCA Non-compartmental analysis  
NDA  New Drug Application  
ACUMIN   Version 3.0 
 19 November,  2018  
 
 
11 NIAID  National Institute of Allergy and Infectious Diseases, NIH, DHHS  
NIH National Institutes of Health  
PD Pharmacodynamics  
PI Principal Investigator  
PK Pharmacokinetics  
QA Quality Assurance 
QC Quality Control 
RRT  Renal Replacement Therapy  
SAE  Serious Adverse Event 
SAEM  Stochastic approximation of the expectation -maximization algorithm 
SAP Statistical Analysis Plan  
SDCC  Statistical and Data Coordinating Center 
SEM  Standard error of the mean  
SMC  Safety Monitoring Committee  
SSR Safety Summary Report  
SUSAR  Suspected Unexpected Serious Adverse Reaction  
TEAE Treatment -Emergent Adverse Events  
Tmax Time at which the maximum plasma drug concentration occurs 
US United States  
USP United States Pharmacopeia  
Vc Volume of distribution in central compartment  
Vp Volume of distribution in the peripheral compartment 
Vss Volume of distribution at  steady state  
WBC  White blood cell count 
WFI Water for injection  
 
 
ACUMIN   Version 3.0 
 19 November,  2018  
 
 
12 PROTOCOL SUMMARY  
Title:  A Phase IV  Open -Label Pharmacokinetic Study of 
Minocycline for Injection Following a Single Infusion in 
Critically -Ill Adults (ACUMIN)  
Phase:  Phase IV 
Population: Up to 67 subjects enrolled to obtain 50 evaluable,  critically -ill 
adults with illness known or suspected to be caused by 
infection with Gram -negative bacteria  
Number of Sites:  Approximately 13 clinical sites  
Study Duration:  Approximately 16 months  
Subject Participation Duration: Approximately 2 days  
Description of Agent or 
Intervention:  Minocin® IV (minocycline hydrochloride injection) 200mg administered intravenously as a single infusion over 
approximately 60 minutes  
Objectives : 
 Primary:  
To characterize minocycline PK at the population level in 
critically -ill adults, with illness known or suspected to be 
caused by infection with Gram -negative bacteria  
To assess patient -level and clinical covariates associated with 
minocycline pharmacokinetic properties in critically -ill adults , 
with illness known or suspected to be caused by infection with Gram -negative bacteria  
 
Exploratory:  
To predict the distribution of concentration- time profiles 
observed with the FDA approved minocycline dosing regimen in critically -ill adults, with illne ss known or suspected to be 
caused by infection with Gram -negative bacteria via 
simulations  
ACUMIN   Version 3.0 
 19 November,  2018  
 
 
13  
To assess whether dosing adjustments for the approved FDA 
minocycline dosing regimen are needed based on identifiable 
patient -level and clinical covariates among critically -ill adults, 
with illness known or suspected to be caused by infection with 
Gram -negative bacteria via simulations  
Conduct simulation studies to determine the ability of the FDA 
approved minocycline dosing scheme to achieve critical 
pharmacokinetic- pharmacodynamic  targets against the range 
of minocycline MIC values observed with infections due to 
Acinetobacter baumannii, including MDR strains 
To evaluate changes of physiological parameters following a 
single infusion of minocycline among criticall y-ill adults.  
Description of Study 
Design:  Unblinded, single-dose, population PK study  
Estimated Time to 
Complete Enrollment:  Approximately 16 months 
ACUMIN                  Version 3.0  
   19 November, 2018  
 
 
14 Figure 1: ACUMIN Study Diagram  
  

ACUMIN   Version 3.0 
 19 November, 2018  
 
 
15 1 KEY ROLES  
Individuals:  
 
   
 
   
 
 Principal Investigator  
Richard G. Wunderink, MD 
Medical Director, Medical Intensive Care Unit  
Northwestern University of Feinberg School of Medicine 240 East Huron,  
McGaw M -336 
Chicago, IL USA 60611 
Phone: 1-312-695-1878 
Email: r-wunderink@northwestern.edu  
 Co-Investigator 
Thomas Lodise, PharmD, PhD 
Professor, Pharmacy Practice  
Albany College of Pharmacy and Health Sciences  
Albany, New York NY 12208 -3492 
Phone:  1-518-694-7292 
Email: Thomas.lodise@acphs.edu   ARLG Project Leader  
Zoë Sund 
300 West Morgan Street, Suite 800 
Durham, NC 27701 Phone:  919-428-1007 Email:  zoe.sund@duke.edu 
  DMID Clinical Protocol Manager   
Marina Lee, PhD  
5601 Fishers Lane, 7E17 
Rockville MD 20852 
Phone: 1-240-627-3304 
Email: marina.lee@nih.gov  
  
 
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
16 DMID Medical Monitor  
Venus Shahamatdar, MD  
5601 Fishers Lane, Room 7E54, MSC 9826 
Bethesda, MD 20892-9826  
Phone: 1-240-627-3369 Email: shahamav@mail.nih.gov  
 
Melinta Therapeutics : Paula M. Bokesch, MD, FAAP Medical Director  
Melinta Therapeutics, Inc. 
44 Whippany Road, Suite 280 
Morris town, NJ 07960 Phone:  
Email:  pbokesch@melinta.com 
 
Safety and Pharmacovigilance 
Contractor:  
 Clinical Research Operations and Management Support 
(CROMS)  
6500 Rock Spring Dr., Suite 650  Bethesda, MD 20814  SAE Hot Line: 1 -800-537-9979 (US)  
SAE Fax: 1-800-275-7619 (US)  
SAE Email: PVG@dmidcroms.com  
 
Statistical and Data 
Coordinating Center:  
 The Emmes Corporation 
401 N. Washington St., Suite 700 
Rockville, MD 20850 Phone: 1-301-251-1161  Email: arlg_studies@emmes.com  
 

ACUMIN   Version 3.0 
 19 November, 2018  
 
 
17 Study Agent Repository:  
 Fisher BioServices  
c/o DMID Clinical Materials Services  Contract  
20439 Seneca Meadows Parkway  
Germantown, MD 20876  
Phone: 1-240-477-1350 Fax: 1-240-477-1360  
Email: DMID. CMS @ThermoFisher.com  
  
PK Laboratory : Syneos Health  
2500, rue Einstein 
Québec, Canada G1P 0A2  
Phone:   
Email: marieeve.coulombe@ syneos health.com  
 
 
 

ACUMIN   Version 3.0 
 19 November, 2018  
 
 
18 2 BACKGROUND INFORMATION AND SCIENTIFIC 
RATIONALE 
2.1 Background Information  
Minocycline is a tetracycline derivative first approved in the United States (US) as both oral and 
intravenous (IV) formulations in the 1970s. The original IV formulation of minocycline was 
approved in the US on 26 October 1972. Rempex Pharmaceuticals, Inc., a wholly owned subsidiary of Melinta Therapeutics , Inc., has developed a new formulation, Minocin
® 
(minocycline) for Injection (referred to as Minocin IV in this protocol), which was approved by the US Food and Drug Administration (FDA) on 17 April, 2015 (NDA 50,444). The new formulation is comprised of minocycline hydrochloride with magnesium sulfate to improve the solubility and stability of minocycline solutions at a more physiological pH, which enables 
administration of minocycline in a smaller volume of fluid. The approved indication for Minocin 
IV includes the treatment of infections due to susceptible strains of several important Gram-positive and Gram-negative pathogens, including Acinetobacter  species.  Minocycline has 
excellent in vitro  microbiologic activity against multi-drug resistant Acinetobacter baumannii  
species ,
1-3 a gro wing world -wide problem.4-9 Furthermore, IV minocycline has been in use for 
over four decades and has a well -established safety profile.  
2.2 Rationale  
This study will examine the pharmacokinetics (PK) of Minocin IV in critically -ill patients with 
Gram -negative infections in the Intensive Care Unit (ICU).  Whil e there is longstanding clinical 
use experience with minocycline in patients, PK studies of minocycline are relatively limited and were conducted in the 1970s in healthy volunteers. Pharmacokinetic data from a single study in 10 healthy male subjects is reported in the USPI and states that following a single dose of 
Minocin IV 200 mg, serum concentrations of minocycline ranged from 2.52 μg/mL to 6.63 
μg/mL (average of 4.18 μg/mL) at the end of infusion and 0.82 μg/mL to 2.64 μg/mL (average of 1.38 mcg/mL) after 12 hours.  The label further states that following administration of Minocin IV 100 mg administered every 12 hours for three days to five healthy male subjects, serum 
concentrations of minocycline ranged from 1.4 μg/mL to 1.8 μg/mL at the end of the dosing 
interval.
10 
More importantly, no published minocycline PK data exists in ICU patients. PK studies of other 
antibiotics in critically ill patients have shown discrepancies between the anticipated PK 
parameters based on healthy volunteers or less ill patients. These differences included altered volumes of distribution, enhanced renal clearance, and altered drug metabolism, ultimately resulting in altered blood concentration time profiles. This study will therefore develop a 
population PK model to describe the PK profile of minocycline in patients in the ICU.  As part of 
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
19 this investigation, we will investigate if patient level and clinical covariates affect the observed 
minocycline PK profile in patients in the ICU.  
2.3 Potential  Risks and Benefits 
2.3.1 Potential Risks  
In general, the re is minimal risk of significant adverse events related to the infusion of Minocin 
IV.  The risk of Minocin IV is consistent with taking an intravenous dose of other tetracycline 
antibiotic.  A single dos e of minocycline is unlikely to select for tetracycline resistance.  
Because of the extensive and long standing use of tetracycline antibiotics there have been many reports of potential drug reactions. 
The following adverse reactions have been observed in patients receiving any tetracyclines and 
are included in the Minocin® (minocycline) for Injection Package Insert.  
Body as a whole:  Fever and discoloration of secretions. 
Gastrointestinal: Anorexia, nausea, vomiting, diarrhea, dyspepsia, stomatitis, glossit is, 
dysphagia, enamel hypoplasia, enterocolitis, pseudomembranous colitis, pancreatitis, and 
inflammatory lesions (with monilial overgrowth) in the oral and anogenital regions. These reactions have been caused by both oral and parenteral administration of tetracyclines.   
Genitourinary: Vulvovaginitis. 
Hepatic toxicity: Hyperbilirubinemia, hepatic cholestasis, increases in liver enzymes, fatal  
hepatic failure, and jaundice. Hepatitis, including autoimmune hepatitis and liver failure, has been reported.  
Skin: Alopecia, erythema nodosum, hyperpigmentation of nails, pruritus, toxic epidermal 
necrolysis and vasculitis, and maculopapular and erythematous rashes. Exfoliative dermatitis has been reported. Fixed drug eruptions have been reported. Lesions occurring on the glans penis 
have caused balanitis. Erythema multiforme and Stevens-Johnson syndrome have been reported.  
Photosensitivity and pigmentation of the skin and mucous membranes have also been reported.  
Local reactions:  Injection site erythema and injection  site pain.  
Respiratory:  Cough, dyspnea, bronchospasm, exacerbation of asthma, and pneumonitis. 
Renal toxicity: Interstitial nephritis. Elevations in blood urea nitrogen (BUN) have been reported 
and are apparently dose- related.  Acute renal failure has been reported.  
Musculoskeletal:  Arthralgia, arthritis, bone discoloration, myalgia, joint stiffness, and joint 
swelling.  
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
20 Hypersensitivity reactions: Urticaria, angioneurotic edema, polyarthralgia,  
anaphylaxis/anaphylactoid reaction (including shock and fatalities), anaphylactoid purpura, 
myocarditis, pericarditis, exacerbation of systemic lupus erythematosus, and pulmonary 
infiltrates with eosinophilia have been reported. A lupus-like syndrome and serum sickness- like 
reactions have also been reported.  
Blood: Agranulocytosis, hemolytic anemia, thrombocytopenia, leukopenia, neutropenia, 
pancytopenia, and eosinophilia have been reported. 
Central nervous system: Convulsions, dizziness, hypoesthesia, paresthesia, sedation, and vertigo.  
Pseudotumor cerebri (benign intracranial hypertension [IH]) in adults and bulging fontanels in 
infants have been reported.  Headache has also been reported.  
Other:   Thyroid cancer has been reported in the post marketing  setting in association with 
minocycline products.  When min ocycline therapy is given over prolonged periods, monitoring  for signs 
of thyroid cancer should be considered.  When given over prolonged periods, tetracyclines have been reported to produce brown-black microscopic discoloration of the thyroid gland.  Cases of 
abnormal thyroid function have been reported. 
Tooth discoloration in pediatric patients less than eight years of age and in adults has been 
reported. 
Oral cavity discoloration (including tongue, lip, and gum) has been reported.  Tinnitus and 
decreased  hearing have been reported.  
The following syndromes have been reported; in some cases involving these syndromes, death has been reported.  As with other serious adverse reactions, if any of these syndromes are 
recognized, the drug should be discontinued i mmediately:  
Hypersensitivity syndrome consisting of cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, and one or more of the following: hepatitis, pneumonitis, nephritis, 
myocarditis, and pericarditis.  Fever and lymphadenopathy ma y be present.  
Lupus- like syndrome consisting of positive antinuclear antibody; arthralgia, arthritis, joint 
stiffness, or joint swelling; and one or more of the following: fever, myalgia, hepatitis, rash, and 
vasculitis.  
Serum sickness -like syndrome consisting of fever, urticarial, or rash; and arthralgia, arthritis, 
joint stiffness, or joint swelling.  Eosinophilia may be present. 
Minocin IV contains subtherapeutic levels of magnesium sulfate heptahydrate. Adverse effects that may be associated with magnesium intoxication include flushing, sweating, hypotension, 
depressed reflexes, flaccid paralysis, hypothermia, circulatory collapse, cardiac and central 
nervous system depression proceeding to respiratory paralysis. 
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
21 2.3.2 Known Potential Benefits  
This is a non- treatment study and subjects are not expected to benefit by receiving the study 
drug.  The study will provide critical PK and PK/PD data in an ICU patient population where 
Minocin IV is likely to be used for the treatment o f Acinetobacter  infections.  
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
22 3 OBJECTIVES  
3.1 Study Objectives  
Primary objectives: 
To characterize minocycline PK  at the population level in critically -ill adults, with illness known 
or suspected to be caused by infection with Gram- negative bacteria. 
To assess patient -level and clinical covariates associated with minocycline pharmacokinetic 
properties in critically -ill adults, with illness known or suspected to be caused by infection with 
Gram -negative bacteria.  
Exploratory objectives: To predict the distribution of concentration-time profiles observed with the FDA approved 
minocycline dosing regimen in critically -ill adults, with illness known or suspected to be caused 
by infection with Gram- negative bacteria via simulations . 
To assess whether  dosing adjustments for the approved FDA minocycline dosing regimen are 
needed based on identifiable patient- level and clinical covariates among critically -ill adults, with 
illness known or suspected to be caused by infection with Gram- negative bacteria via 
simula tions.  
Conduct simulation studies to determine the ability of the FDA approved minocycline dosing 
scheme to achieve critical pharmacokinetic -pharmacodynamic  targets against the range of 
minocycline MIC values observed with infections due to Acinetobacter baumannii, including 
MDR strains. 
To evaluate changes of physiological parameters following a single infusion of minocycline 
among critically -ill adults.  
 
3.2 Study Outcome Measures  
3.2.1 Primary Outcome Measures  
Population mean PK parameter estimates and the magnitude of the associated inter -individual 
variability for free -drug and total-drug clearance (CL), central volume of distribution (Vc), 
distribution clearance (CLd), and the peripheral volume of distribution (Vp), determined using nonlinear mixed effects mode ling on PK time points collected up to 48 hours after a single-dose 
on Day 1.   
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
23 Individual post- hoc PK parameter estimates and calculated exposure measures after a single dose 
such as the maximum plasma concentration (C max), the plasma concentration at 24 hours after a 
dose (C 24), the area under the curve from 0 to 24 hours after a dose (AUC 0-24), the area under the 
curve to the last quantifiable sample (AUC 0-last), and area under the curve from 0 to infinity 
(AUC 0-inf) using both free-drug and total- drug c oncentrations. 
3.2.2 Exploratory Outcome Measures  
Distribution of simulated concentration -time profiles with the FDA approved minocycline dosing 
regimen across the patient -level and clinical covariates patterns in the final population PK model.   
Comparison of the observed simulated concentration- time profiles in critically -ill adults, with 
illness known or suspected to be caused by infection with Gram- negative bacteria with simulated 
concentration -time profiles in healthy adults.   If needed, dose adjustment calculations will be 
made.  
Probability of achieving free- drug AUC:MIC ratio ( fAUC:MIC) ≥ 12 (PK- PD target for bacterial 
stasis), and probability of achieving f AUC:MIC  ratio ≥ 18 (PK- PD target for 1 -log 10 CFU kill), 
for FDA -approved minocycline dosing regimens. 
Change from baseline at 48hr post-dose in :  
liver function tests  
magnesium  
serum creatinine  
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
24 4 STUDY DESIGN  
This is a Phase IV, multi- center open -label pharmacokinetic trial studying the pharmacokinetics 
and pharmacodynamics of a single dose of Minocin IV in up to 50 evaluable, ICU patients who 
are already receiving antimicrobial therapy for a known or suspected Gram -negative infection. 
Once patients are confirmed as eligible, and informed consent is obtained, patients will be 
enrolled into the study. 
Each subject will receive a single 200  mg dose of Minocin IV infused over approximately 60 
minutes.  Each subject will have 7 PK samples collected (1 pre-dose, 6 post-dose) at de signated 
time points over a ~48 hour period f ollowing the start of the Minocin IV infusion.   
Blood specimens will be processed and shipped on dry ice to a central laboratory where total and 
free minocycline levels will be analyzed.  Data will be reported back to Emmes , and will be 
shared with Albany College of Pharmacy and Emmes  for PK  modeling .  The data will be 
analyzed using a population pharmacokinetic approach with covariate model building.   
Enrollment is estimated to be completed in approximately 1 6 months.  There will not be any 
stratification.  Subjects will be expected to be in the trial for approximately 2 days  after they are 
enrolled . Additional follow-up may be required.  
Up to 67 subjects will be enrolled in order to obtain 50 PK evaluable subjects in the study.   To be 
considered PK evaluable, a subject must (1) have the baseline pre- dose PK sample collected (2) 
receive the full infusion of study drug, (3) have at least 3 PK samples collected in the first 12 
hours post dose, (4) have at least 1  PK sample collected 24 -48 hours post dose, and (5) PK 
specimens processed per the Manual of Procedures.  
For subjects who receive the full infusion of study drug but are not PK evaluable, their available PK data may still be used in the final PK analyses i f certain criteria listed in the Statistical 
Analysis Plan are met.  
 
  
 
  
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
25 5 STUDY ENROLLMENT AND  WITHDRAWAL 
5.1 Subject Inclusion Criteria  
Subjects must meet all of the following criteria in order to be eligible for the study:  
1. Male or female ≥18 years of age 
2. Subject is in the ICU, or is being admitted to the ICU  
3. Known or suspected Gram-negative infection for which the subject is receiving systemic 
antibiotics, and which was the reason for admission to the ICU, or reason for persistent need for ICU care  
4. Expectatio n, in the judgment of the investigator, that the subject will remain admitted in 
the hospital for at least 48 hours following enrollment and that all study procedures will be completed  
5. Expectation that intravenous access will be sufficient for drug infusion and either 
intravenous or arterial  access  will be sufficient to allow for all protocol required blood 
sampling to occur 
6. The subject , or legal ly authorized representative (LAR) , is able and willing to provide 
signed informed consent 
5.2 Subject Exclusion Criteria 
Subjects who meet any of the following criteria at baseline will not be enrolled in the study:  
1. History of significant hypersensitivity or allergic reaction to tetracycline antibiotics  
2. Receipt of oral or intravenous tetracycline class drugs within 7 days of enrollment (e.g., 
minocycline, tetracycline, tigecycline, doxycycline)  
3. Use of isotretinoin within 2 weeks of enrollment into the study 
4. Major surgery1 within 48 hours prior to enrollment 
5. Pregnant or breastfeeding women  
6. Patient is being treated for  intracranial hypertension  
7. Any condition that, in the judgment of the investigator, precludes participation because it could affect subject safety  
2 
                                                 
 
 

ACUMIN   Version 3.0 
 19 November, 2018  
 
 
26 8. Receipt of an investigational study product within 7 days prior to  enrollment.  
Investigator discretion should be used when longer acting agents have been used in the 
previous 30 days 
  
1 Major surgery is defined as “the opening of either a body cavity or the mesenchymal barrier, using general 
anesthesia”  
2 Subjects on, or who may be considered for Renal Replacement Therapy (RRT) during the study period are not 
excluded from participating in the study . 
 
5.3 Treatment Assignment Procedures  
5.3.1 Randomization Procedures  
This is a single arm study. There are no randomization procedures.  Subjects will be enrolled 
online through the enrollment module of AdvantagEDCSM, the Emmes Corporation’s Internet 
Data Entry System (IDES).  Instructions for use of the enrollment module are included in the AdvantagEDC
SM User’s Guide.  Manual back-up enrollment procedures are provided in the 
MOP for use in the event that the site temporarily loses access to the internet or the online 
enrollment system is unavailable.  
5.3.2 Masking Procedures  
This is an unblinded study. Masking is not needed. 
5.3.3 Reasons for Study Withdrawal 
All subjects have the right to withdraw at any point during treatment without prejudice.  A 
subject may withdraw or be withdrawn from this study for any of the following reasons: 
• Medical disease or condition, or any new clinical findings for which continued 
participation, in th e opinion of the site principal investigator or appropriate sub-
investigator, would compromise the safety of the subject, or would interfere with the 
subject's successful completion of the study, or would interfere with the evaluation of responses. 
• As deemed necessary by the site principal investigator or appropriate sub- investigator for 
noncompliance or other reasons. 
• Subject withdrew consent.  
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
27 The investigator can discontinue any subject’s Minocin infusion at any time if medically 
necessary.  The reaso n(s) for early discontinuation should be reflected in the source 
documentation and on the appropriate eCRF.   
5.3.4 Handling of Withdrawals  from the PK Analysis 
In all cases, the reasons why a subject is withdrawn must be recorded into the eCRF.  Subjects 
who ar e not evaluable for the PK analysis will be replaced .  Refer to  Section 4 for the definition 
of an evaluable subject . 
5.3.5 Termination of Study  
The DMI D/NIAID, ARLG, FDA and/or Rempex Pharmaceuticals, Inc. /Melinta Therapeutics 
Inc. have the right to discontinue this study at any time for medical and/or administrative 
reasons.  For subjects  who received minocycline prior to the termination of the study, all safety 
related procedures described  in this protocol should be performed.   
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
28 6 STUDY INTERVENTION/I NVESTIGATIONAL 
PRODUCT 
6.1 Study Product Description  
Minocin IV is a sterile formulation of a semisynthetic derivative of tetracycline. The chemical 
name of m inocycline is 4,7- Bis(dimethylamino) -1,4,4a,5,5a,6,11,12a- octahydro -3,10,12,12a- 
tetrahydroxy -1,11-dioxo-2-naphthacenecarboxamide monohydrochloride. 
Its structural formula is:  
Figure 2: Structural Formula of Minocin IV  
 
C23H27N3O7•HCl M.W. 493.94 
6.1.1 Acquisition  
Minocin IV will be supplied by Rempex Pharmaceuticals, Inc., a wholly owned subsidiary of Melinta Therapeutics, Inc.    
Sterile water for injection, USP and 0.9% Sodium Chloride, USP (normal saline) will be 
supplied by each participating site . 
Study product will be shipped to the investigational site upon request and approval by DMID. 
6.1.2 Formulation, Packaging, and Labeling 
6.1.2.1 Minocin IV  
Minocin IV is supplied as a sterile yellow to amber lyophilized powder for intravenous infusion 
in a single -use 10 mL glass vial with a rubber stopper and aluminum overseal. Each vial 
contains108 mg of minocycline hydrochloride (equivalent to 100 mg of minocycline) , 269 mg 
magnesium sulfate heptahydrate (2.2 mEq of magnesium) (an inactive ingredient) and sodium hydroxide (to adjust pH). When reconstituted with 5 mL of Sterile Water for Injection USP the pH ranges from 4.5 to 6.0.  Further information can be found in the Manual of Procedures  and 
Minocin
® (minocycline) for Injection Package Insert.  

ACUMIN   Version 3.0 
 19 November, 2018  
 
 
29 6.1.2.2 Sterile Water for Injection  (WFI) , USP  
The sterile water for injection (WFI), USP is nonpyrogenic and contains no bacteriostatic, 
antimicrobial agent, or added buffer.  This product should be used to reconstitute the Minocin IV vial.  WFI will be obtained as a single -dose container.   
6.1.2.3 0.9% Sodium Chloride, USP (Normal Saline)  
0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection.  Each mL contains 9 mg of sodium chloride and contains no 
preservatives, bacteriostatic, antimicrobial agent, or added buffer.  The solution is clear in 
appearance and may contain hydrochloric acid and/or sodium hydroxide for pH adjustment (pH 
5.3 [4.5 to 7.0]).  Normal saline will be obtained in 100 mL IV bags a nd will be used to dilute the 
Minocin IV  for intravenous infusion.  
6.1.3 Product Storage and Stability  
6.1.3.1 Minocin IV  
Vials containing lyophilized Minocin IV are stored at controlled room temperature of 20°C to 25°C (68°F to 77°F). Per the USP controlled room tempe rature requirement, excursions between 
15°C and 30°C (59°F and 86°F) are permitted . Once reconstituted, Minocin IV bags can be 
stored at room temperature for up to 4 hours or refrigerated at 2°C to 8°C (36°F to 46°F) for up 
to 24 hours.  Further details can be found in the Manual of Procedures and Minocin
® 
(minocycline) for Injection Package Insert.  
6.1.3.2 Sterile Water for Injection  (WFI) , USP  
The sterile WFI vials are stored at 20ºC to 25ºC (68°F to 77ºF) [See USP Controlled Room 
Temperature; excursions between 15°C and 30°C (59°F and 86°F) are permitted].  
6.1.3.3 0.9% Sodium Chloride, USP (Normal Saline)  
Store at 20ºC to 25ºC (68°F to 77ºF) [See USP Controlled Room Temperature; excursions 
between 15°C and 30°C (59°F and 86°F) are permitted].  Protect from freezing. 
6.2 Dosage, Preparat ion and Administration of Study 
Intervention/Investigational Product  
Two-100 mg vials of Minocin IV are required for each single dose.  The lyophilized powder in 
each vial (approximately 108 mg/vial, equivalent to 100 mg upon reconstitution) should be 
reconstituted  with 5  mL of Sterile Water for Injection (10mL total).  10 mL should be removed 
from the 100 mL bag of Sodium Chloride Injection, USP.  The contents of the two reconstituted vials of Minocin IV should be transferred aseptically to the bag of Sodium Chloride Injection 
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
30 USP, and then mixed by inversion. Once diluted into an intravenous bag, the infusion may be 
stored at room temperature  (20° to 25°C) and administered within  4 hours, or refrigerated at 2 to 
8°C (36 to 46°F) and administer ed within 24 hours of preparation.  
Subjects will receive a single 200 mg intravenous infusion of Minocin IV in 100 mL of normal 
saline  administered at  a rate of 100  mL/ hour and until the bag is empty and the line is flushed .  
Additional study product preparation details are further described in the protocol- specific 
Manual of Procedures.   
6.3 Modification of Study Intervention/Investigational Product for a 
Subject  
This is a single dose study. There will be no dose modifications pe rmitted.    
6.4 Accountability Procedures for the Study Intervention/Investigational 
Product(s)  
The site principal investigator is responsible for the distribution and disposition of study product, 
and has ultimate responsibility for accountability.  The site principal investigator may delegate 
this responsibility to the site Research Pharmacist.  If delegated, the site Research Pharmacist 
will be responsible for maintaining complete records and documentation of study product receipt, accountability, dispensation, temperature monitoring, and storage conditions, and final 
disposition of the study product.   
All study products, whether administered or not, must be documented on the appropriate study 
product accountability record or dispensing log.  Used and unused Minocin IV vials will be retained until monitored and then released for disposition.  Any unused solution left in the IV 
infusion bag or IV administration tubing after administration to the subject should be discarded 
as biohazardous waste.  
Upon completion of the study and after the final monitoring visit, any remaining unused study 
product will either be returned or destroyed appropriately at the clinical site as per sponsor 
requirements and instructions, or in accordance with disposition plans. 
6.5 Assessme nt of Subject Compliance with Study 
Intervention/Investigational Product  
Study drug compliance including start and stop time of infusion, volume administered, and the occurrence of any infusion interruptions (greater than 10 minutes) will be captured in the source documents. 
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
31 6.6 Concomitant Medications/Treatments  
In this study, a single dose of Minocin IV is being administered, and as such, is unlikely to result 
in significant medication interaction.  However, the following are listed in the Minocin® 
(minocycline) for Injection Package Insert as precautions or warnings:  
Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are 
on anticoagulant therapy may require downward adjustment of their anticoagulant dosage.  
Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable 
to avoid giving tetracyclines in conjunction with penicillin.  
The concurrent use of tetracyclines and methoxyflurane has been reported to result in fatal renal 
toxicity.  
Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.  
Administration of isotretinoin should be avoided shortly before, during, and shortly after minocycline therapy. Each drug alone has been associated with pseudotumor cerebri.  
Increased risk of ergotism when ergot alkaloids or their derivatives are given with tetracyclines.  
Minocin IV contains magnesium sulfate heptahydrate. Potentially serious drug interactions may 
occur when intravenous magnesium sulfate heptahydrate is given concomitantly with CNS 
depressants, neuromuscular blocking agents and cardiac glycosides. 
Concomitant and treatment medications  will be collected  from 24 hours prior to the start of 
infusion through 48 hours post start of  infusion (total of 72 hours) , as well as  the SAE follow-up 
visit as needed . 
Receipt of any renal replacement therapies  (RRT)  will be collected from 1 hour post start of 
infusion through 48 hours post start of infusion. 
  
  
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
32 7 STUDY SCHEDULE  
The foll owing sections describe the study procedures and data collected. For each procedure, 
subjects are to be assessed by the investigator or site personnel. A Schedule of Ev ents is located 
in Appendix A . 
7.1 Screening (within 48 hours of enrollment ) 
Informed consent must be obtained prior to the subject entering into the study, and before any 
protocol- directed procedures are performed.  Subjects will be screened in accordance with 
predefined inclusion and exclusion criteria as described in Section 5. 
Subjects /LAR s will be provided with a description of the study (purpose and study procedures) 
and asked to read and sign the informed consent form. After the subject has provided informed consent to participate in the study, screening will include: 
Review eligibility criteria with the subject and/or LAR  
Complete medical history 
 
Demographic  information (age, gender, race, ethnicity)   
Height  (can  be pulled from medical records associated with the current hospital admission OR 
collected within the screening window) 
Targeted physical examination  
Vital signs  
Collect concomitant medications (starting  24 hours prior to start of infusion) 
Clinical laboratory evaluations to include (see Section 8.2.1 for complete list of tests) *: 
Blood c hemistry  
Serum creatinine (if not included in clinical chemistry)  
Liver function te sts 
Hematology  
Magnesium  
Urinalysis  
Serum hCG pregnancy test, from women of childbearing potential 
* Standard of care results obtained for clinical care purposes within 48hrs of screening are acceptable for screening. 
A pregnancy test at any time during the current hospitalization is acceptable for screening.  
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
33 7.2 Baseline  (Dosing – 0 hrs ) 
If the subject has satisfied all of the inclusion criteria and none of the exclusion criteria, the 
subject should be enrolled as described in Section 5.3. The following procedures will be 
completed:  
Blood c hemistry (if not collecte d within 8 hours prior to  the start of study drug infusion) 
Liver function tests (if not collecte d within 8 hours prior to the start of study drug infusion) 
Hematology (if not collecte d within 8 hours prior to the start of study drug infusion) 
Vital signs, collected as close to the start of the study drug infusion as possible 
Weight, collected as close to the start of the study drug infusion as possible 
PK blood samples, collected just prior to  the start of  study drug infusion 
Serum creatinine , collected just prior to  the start of study drug infusion 
Magnesium , collected just prior to  the start of study drug in fusion 
Administration of a single dose of Minocin IV in the ICU under the supervision of the investigator or designee  
Collection of concomitant medications, including IV medications administered during the time 
of Minocin infusion (refer to the Manual of Procedures for details)  
Serious a dverse event collection (SAEs will be collected from the start of the investigational 
drug infusion and will continue for 24 hours from that point.) 
7.3 1-24 hour  Study Visits (post start of infusion)  
Vital signs collected at 1  hour and at 24 hours  
Weight  collected at 24  hour s 
Collection of concomitant medications, including IV medications administered (refer to the 
Manual of Procedures for details) 
Collection of any RRTs being received  
Serious a dverse event collection  (SAEs will be collected from the start of the investigational 
drug infusion and will continue for 24 hours from that point.)  PK blood samples collected at the following time points: Immediately after the end of infusion (1 
hour), 4 hours, 12 hours and 24 hours  
Serum creatinine collected at the following time points: Immediately after the end of infusion (1 
hour), 4 hours, 12 hours and 24 hour s 
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
34 Magnesium collected at 24 h ours  
Hematology at 24 hours  
NOTE:  Study time point windows are detailed in the S chedule of Events ( Appendix A ) 
7.4 36 hour  Study Visit (post start of infusion)  
Subjects will undergo the following procedures:  
Collection of concomitant medications, including IV medications administered (refer to the 
Manual of Procedures for details) 
PK blood samples collected at 36 hours 
Serum creatinine collected at 36 hours Collection of any RRTs being received  
Follow-up on any reported SAEs NOTE:  Study time point windows are  detailed in the S chedule of Events  (Appendix A ) 
7.5 48 hour Time Point (Final Study Visit ) 
The final study visit will occur at 48 hours after the start of infusion. Subjects will undergo the 
following procedures:  Vital signs collected at 48 hours  Hematology at 48 hours  
Weight  
Collection of concomitant medications, including IV medications (refer to the Manual of 
Procedures for details)  
Collection of any RRTs being received  
Follow-up on any reported SAEs 
PK blood samples collected at 48 hours Clinic al laboratory evaluations to include:  
Liver function tests Serum creatinine  
Magnesium  
NOTE:  Study time point windows are  detailed in the S chedule of Events ( Appendix A ) 
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
35 7.6 SAE Follow -up Visit  (as needed)  
Targeted physical examination  
Vital signs  
Collect concomitant medications  
Clinical laboratory evaluations , as needed   
Follow-up on any SAEs  
7.7 Early Termination Visit  
If a subject is terminated early, the reason for termination must be documented in the source 
document and e CRF.  If at all possible, vital signs and laboratory tests obtained for clinical 
purposes should be recorded at early termination.  
7.8 Unscheduled Visit s  
Unscheduled visits will occur at the investigators discretion.  
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
36 8 STUDY PROCEDURES/EVALUATIONS  
8.1 Clinical Evaluations  
The study protocol must be strictly adhered to.  Any modifications that become necessary or 
desirable must be documented in writing.  Amendments or changes to the protocol require the 
approval of the investigator and the Institution Review Board (IRB). Any protocol deviations 
will be documented.  
Complete medical history will be obtained by interview of the subject or subject’s LAR during 
screening.  Subject will be queried regarding a history of significant medical disorders and any 
allergies.   
RRT data will be collected for subjects who undergo RRT, starting one hour  from the start of 
the minocycline infusion through 48 hours post infusion, per the Manual of Procedures. 
Medications  history (concomitant medications) will include a review of all medications  taken 
within 24 hours prior to start of infusion, through 48 hours post infusion, as well as the SAE 
follow-up visit as needed. Pertinent data for concomitant medications will be documented  per the 
Manual of Procedures. Per the exclusion crit eria, the following medications will also be 
documented: 
Isotretinoin within 2 weeks prior to enrollment Tetracycline class drugs within 7 days prior to enrollment 
Any investigational product within 7 days prior to enrollment 
A targeted physical examination  and examination of specific systems to be guided by 
symptomatology, will be performed during screening , as well as the SAE follow -up as needed .  
All physical examinations will be performed by a study clinician licensed to make medical 
diagnoses.  
Vital signs, including systolic and diastolic blood pressures (mm Hg), heart rate (HR) ,   
respiratory rate, and temperature will be recorded  at the indicated time points.  Please refer to the 
Manual of Procedures for details. 
Height  and weight will be measured  or calculated per the Manual of Procedures, rather than 
estimated or by report of relative.   
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
37 8.2 Laboratory Evaluations  
8.2.1 Clinical Laboratory Evaluations 
Hematology, clinical chemistry, and urinalysis will be carried out according to standard 
operating procedures used by the clinical laboratory at each site.  
Each site will maintain a list of the normal ranges and units of measurement for the laboratory 
parameters to be determined during this study, and the data and certification number of the 
laboratory.  If the normal ranges change during the course of the study, the site investigator must update this list with the new ranges and effective dates.  The normal laboratory reference ranges 
will also be retained in the Regulatory Binder at each site. Laborato ry tests will be obtained from 
screening through the final study visit (48 hours). Refer to the Schedule of Events located in 
Appendix A . The laboratory tests to be performed are listed below.  
Hematology - hemoglobin, hematocrit, white blood cell count (WBC) , WBC differential, red 
blood cell count, platelets 
Clinical chemistry  - potassium, sodium, chloride, bicarbonate, glucose, blood urea nitrogen, 
serum creatinine  
Liver function tests:  AST, ALT, alkaline phosphatase, albumin, total bilirubin  
Magnesium  
Serum hCG pregnancy test (females of child bearing potential only)   
Urinalysis - protein, glucose, ketones, bilirubin, blood, nitrites, LCE, urobilinogen, specific 
gravity,  and pH  
8.2.2 Special Assays or Procedures  
Pharmacokinetic blood samples will be collected  at the appropriate time points.  Plasma will be 
separated and stored frozen, preferably  at -80°C; however, use of a -20°C freezer  prior to 
shipping to central lab is permissible but must not exceed 2 weeks.  Plasma PK samples will be 
analyzed for both free and total minocycline concentrations in plasma using a validated liquid 
chromatography assay with mass spectrophotometry detection (LC- MS). Please refer to the 
Manual of Procedures for more complete details.  
8.2.3 Specimen Preparation, Handling, and Shipping  
8.2.3.1 Instructions for Specimen Preparation, Handling, and Storage  
Specimen preparation, handling and storage instructions are included in the Manual of Procedures . 
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
38 8.2.3.2 Specimen Shipment  
Specimen shipment instructions are included in the Manual of Procedures.  
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
39 9 ASSESSMENT OF SAFETY  
9.1 Specification of Safety Parameters  
Minocin IV is an approved drug with an established safety profile. As such, no safety outcomes 
are assessed through this study.   
9.2 Methods and Timing for Assessing, Recording, and Analyzing Safety 
Parameters  
9.2.1 Adverse Events  
In this study a single 200 mg infusion of Minocin IV is being administered.  As this is an 
approved product at an approved dose, and the study is being performed in subjects in the ICU 
who will have multiple events  due to their underlying disease, only SAEs will be captured in this 
protocol.   
9.2.2 Serious Adverse Events  
An adverse event is considered “serious” if, in the view of either the investigator or sponsor, it 
results in any of the following outcomes:  
Death,  
A life -threatening adverse event,2  
Inpatient hospitalization or prolongation of existing hospitalization,  
A persistent or significant incapacity or substantial disruption of the ability to conduct normal 
life functions, or  
A congenital anomaly/birth defect.   
Important medical events that may not result in death, be life -threatening, or require 
hospitalizations may be considered serious when, based upon appropriate medical judgment they 
may jeopardize the subject and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition.  Examples of such medical events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias 
                                                 
 
2 Life-threatening adverse event. An adverse event is considered “life- threatening” if, in the view of either the 
investigator or sponsor, its occurrence places the patient or subject at immediate risk of death.  It does not include an 
adverse event, had it occurred in a more severe form,  that might have caused death. 
 

ACUMIN   Version 3.0 
 19 November, 2018  
 
 
40 or convulsions that do not result in inpatient hospitalization, or the development of drug 
dependency or drug abuse. 
All SAEs will be:  
recorded on the app ropriate SAE eCRF  
followed through resolution by a study clinician reviewed and evaluated by a study clinician  
SAEs will be collected from the start of the investigational drug infusion and will continue for 24 
hours from that point. As the study population in this protocol are critically ill patients, the utility 
of SAE collection (i.e., the ratio between true safety signal and all events that meet the SAE criteria), might be low. The study team will evaluate the utility of SAE collection on a regular 
basis and will consider change in duration, scope or intensity of SAE collection. Any changes in 
SAE collection will only be implemented following a protocol amendment.  
Timing of Recording and Reporting of SAEs 
Serious Adverse Events (SAEs) will be recorded a nd reported from the start of the Minocin IV 
infusion until 24 hours from the start of infusion.  All SAEs will be followed until resolution or 
stabilization.  Resolution of an SAE is defined as the return to baseline or stabilization of the condition with the expectation that it will remain chronic.  
All SAEs must be graded for severity and relation ship to study product.  
Severity of Event:   
SAEs will be assessed by a licensed  study physician listed on the Form FDA1572 as the site 
principal investigator or appropriate sub-investigator. The following guidelines will be used to 
quantify intensity.  
Mild:     Events require minimal or no treatment and do not interfere with the subject’s 
daily activities.  
Moderate:   Events result in a low level of inconvenience or concern with the therapeutic 
measures. Moderate events may cause some interference with fu nctioning. 
Severe:   Events interrupt a subject’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually incapacitating.  
Changes in the severity of an AE should be documented to allow an assessment of the duration 
of the event at each level of intensity to be performed.  Adverse events characterized as intermittent require documentation of onset and duration of each episode. 
 
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
41 Relationship to Study Products:   
The clinician’s assessment of an SAE's relationsh ip to study drug is part of the documentation 
process, but it is not a factor in determining what is or is not reported in the study.  If there is any 
doubt as to whether a clinical observation is an SAE, the event should be reported.  All S AEs 
must have their relationship to study product assessed using the terms:  related or not related.  In 
a clinical trial, the study product must always be suspect.  To help assess, the following guidelines are used. 
Related  – There is a reasonable possibility that the study product caused the adverse event. 
Reasonable possibility means that there is evidence to suggest a causal relationship between the 
study product and the adverse event. 
Not Related  – There is not  a reasonable possibility that the administration of the study product 
caused the event.  
9.2.3 Expectedness  
Expectedness will be based on adverse events based on the current label.  
9.3 Reporting Procedures  
All SAEs that occur from the start of infusion through 24 hours after the start of infusion will be 
reported. 
9.3.1 Serious Adverse Events  
SAEs will be followed until resolution even if this extends beyond the study-reporting period.  
Resolution of an SAE is defined as the return to pretreatment status or stabilizatio n of the 
condition with the expectation that it will remain chronic.  
Any SAE that meets a protocol- defined serious criterion must be submitted immediately 
(within 24  hours of site awareness) on an SAE form to the DMID Pharmacovigilance 
Group, at the following address:  
DMID Pharmacovigilance Group 
Clinical Research Operations and Management Support (CROMS)  
6500 Rock Spring Dr. Suite 650 
Bethesda, MD 20814, USA 
SAE Hot Line: 1 -800-537-9979 (US) or 1-301-897-1709 (outside US) 
SAE FAX Phone Number: 1 -800-275-7619 (US) or 1-301-897-1710 (outside US) 
SAE Email Address: PVG@dmidcroms.com  
Other supporting documentation of the event may be requested by the DMID Pharmacovigilance Group and should be provided as soon as possible.  
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
42 The DMID medical monitor and clinica l protocol manager will be notified of the SAE by the 
DMID Pharmacovigilance Group.  The DMID medical monitor will review and assess the SAE 
for regulatory reporting and potential impact on study subject safety and protocol conduct.  
At any time after completion of the study, if the investigator becomes aware of an SAE that is 
suspected to be related to study product, the investigator will report the event to the DMID Pharmacovigilance Group.  
9.3.2 Regulatory Reporting for Studies Conducted Under DMID -Sponsored IND 
Following notification from the investigator, DMID, the IND sponsor, will report any suspected 
adverse reaction that is both serious and unexpected.  DMID will report an adverse event as a suspected adverse reaction only if there is evidence to suggest a causal relationship between the drug and the adverse event.  DMID will notify FDA and all participating investigators (i.e., all 
investigators to whom the sponsor is providing drug under its INDs or under any investigator’s 
IND) in an IND safety report of potential serious risks from clinical trials or any other source, as 
soon as possible, but in no case later than 15 calendar days after the sponsor determines that the 
information qualifies for reporting as specified in 21 CFR Part 312.32. DMID will also notify 
FDA of any unexpected fatal or life- threatening suspected adverse reaction as soon as possible 
but in no case later than 7 calendar days after the sponsor’s initial receipt of the information. Relevant follow up information to an IND safety report will be submitted as soon as the 
information is available.  Upon request from FDA, DMID will submit to FDA any additional 
data or information that the agency deems necessary, as soon as possible, but in no case later than 15 calendar days after receiving the request.  
All serious events designated as “not related” to study product(s), will be reported to the FDA at 
least annually in a summary format.  
9.3.3 Reporting of Pregnancy 
Pregnancy occurring during a clinical investigation, although not considered a SAE, must be 
reported within the same timelines as a n SAE. The positive pregnancy test should be recorded in 
the database within 5 days of site awareness, on the Pregnancy Report form.  The report will include pregnancy outcome (e.g., any premature terminations, elective or therapeutic, any spontaneous abortions or stillbirths), as well as the health status of the mother and child, 
including date of delivery and infant’s sex and weight.  Pregnancies will be followed until birth. 
If the database is locked at time of pregnancy, a supplemental report will be generated and 
completed after birth, which will be appended to the database.  Any occurring AEs or SAEs that 
occur to the mother or fetus will be recorded in the AE or SAE eCRF in the database.  
Sites are responsible for notifying their local IRBs of any pregnancies in accordance with local 
policies.   
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
43 9.4 Type and Duration of Follow -up of Subjects after Serious Adverse 
Events  
All SAEs will be followed until resolution or stabilization.  
9.5 Halting Rules  
Further enrollment will be halted for safety monitoring committee ( SMC ) 
review/recommendation if any SAE meets the SUSAR  criteria . 
9.6 Safety Oversight (SMC)  
Safety oversight will be conducted by a SMC which is an independent group of experts that 
monitors subject safety and advises DMID.  Members of the SMC will be separate and independent of study personnel participating in this study and should not have scientific, 
financial or other conflict of interest related to the study.  The SMC will consist of at leas t 3 
voting members with appropriate expertise to contribute to the interpretation of the safety data 
from this trial. In addition, DMID can request the ad- hoc review of safety events by a local 
independent assessor at the clinical site  
The SMC meetings for  data review are as follows:  
Organizational meeting (prior to start of the study)  
Data Review Meetings (DRM) will be held during the study:  
An ad hoc SMC meeting will be convened when a halting rule is met, or at the request of the investigator and/or DMI D if there are safety concerns during the course of the study.  
Annually for aggregate review of SAEs. 
Final Data Review Meeting: 6 -8 months after clinical database lock to review the cumulative 
unblinded safety data for this trial.  The data will be provided in a standard summary format.  
The SMC will operate under the rules of a DMID -approved charter. Data reviews may include 
enrollment and demographic information, medical history, concomitant medications, physical 
assessments, dosing compliance, protocol a dherence, clinical laboratory values, PK data, and 
SAEs. Additional data may be requested by the SMC, and interim statistical reports may be 
generated as deemed necessary and appropriate by DMID. The SMC will receive data in aggregate. The objective of the SMC is to make recommendations to the sponsors if the study 
should continue per protocol, be modified and then proceed, or be terminated.  After each 
review/meeting the SMC will make recommendations as to the advisability of proceeding with study (as applicable), and to continue, modify, or terminate this trial. 
The DMID Medical Monitor is empowered to stop study enrollment and administration if the 
halting criteria is met or if any serious safety concerns arise.   
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
44 10 CLINICAL MONITORING  
A separate clinical m onitoring plan will be developed to describe who will conduct the 
monitoring, what frequency of monitoring will be done, and what level of detail monitoring will 
be performed.   
10.1 Site Monitoring Plan  
Site monitoring is conducted to ensure that the human subject protection, study procedures, laboratory, study intervention administration, and data collection processes are of high quality and meet the sponsor, ICH E6 and, when appropriate, regulatory guidelines.  This section 
provides a general description of h ow site monitoring will be conducted.  A separate monitoring 
plan document will be developed to describe who will conduct the monitoring, at what frequency 
monitoring will be done, and what level of detail monitoring will be conducted.   
The monitoring plan must include the number of subject charts to be reviewed, which/what 
proportion of data fields and what will be monitored, and who will be responsible for conducting the monitoring visits . 
The sponsor has ethical, legal and scientific obligations to carefully follow this study in 
accordance with established research principles and applicable regulations.  The investigator, as 
part of his responsibilities, is expected to cooperate with the Sponsor in ensuring that the study adheres to the protocol and GCP requirements.   
As part of a concerted effort to fulfill these obligations, the sponsor's monitor (or designee) will 
visit the center(s) during the study in accordance with the Monitoring Plan set forth for this trial.  The investigator will permit the Spo nsor to monitor the study as frequently as is deemed 
necessary and provide access to medical records/source documents to ensure that data are being 
recorded adequately, that data are verifiable and that protocol adherence is satisfactory.   
 
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
45 11 STATISTICAL CO NSIDERATIONS 
Detailed methodology for summary and statistical analyses of the data collected in this trial will 
be documented in a Statistical Analysis Plan (SAP). This document may modify the plans 
outlined in the protocol; however, any major modifications of the primary endpoints definition and/or its analysis will also be reflected in a protocol amendment. Additional statistical analyses other than those described in this section may be performed if deemed appropriate and included 
in the plan.  
This is a n observational, single-arm, single- dose, open-label study of the pharmacokinetics and 
pharmacodynamics of Minocin IV in up to 50 ICU patients who are already receiving 
antimicrobial therapy for a known or suspected Gram-negative infection.  Each subject w ill 
receive a single 200mg dose of Minocin IV infused in normal saline over approximately 60 minutes, after which the subject will have PK samples collected at designated time points over a ~48 hour period following the Minocin IV infusion.  To be considered PK evaluable, a subject 
must have the baseline pre- dose PK sample collected, receive the full infusion of study drug, 
have at least 3 PK samples collected in the first 12 hours post dose, have at least 1 PK sample 
collected 24 -48 hours post dose, and PK specimens must be processed per the Manual of 
Procedures .
 
 For PK specimens collect ion and process ing details, please refer to the Manual of Procedures.  
11.1 Study Hypotheses  
The aim of the study is to characterize the PK of minocycline, administered as a single dose of 
Minocin IV, in critically ill subjects.  As such, no formal hypothesis testing will be performed.  The final population PK model will generate a population mean for each PK parameter; 
statistical inference will consist of associated 95% confidence intervals (CIs) around the 
parameter estimates, including estimates of the effects of patient -level and clinical covariates.   
The final population PK model will also be used to generate individual patient- specific PK 
parameters (CL, Vc, CLd and Vp) which will be used to calculate C
max, AUC 0-24, AUC 0-last, and 
AUC 0-inf.and C 24.  
To assess the probability of attaining PK- PD targets associated with microbiologic efficacy 
(achievement of fAUC:MIC targets associated with bacterial stasis and 1 -log kill for A. 
baumannii ) , Monte Carlo simulations will be conducted.  Simulations may also be used to 
assess the probability of target attainment for specific subgroups of patients and for alternate dosing strategies.  
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
46 11.2 Sample Size Considerations  
The sample size for this study was selected in accordance with current guidance for PK studies.11  
11.3 Planned Interim Analyses  
No interim analyses are planned.  A safety summary report will be generated for SMC review if 
the halting rule (see Section 9.5) is met.  
11.3.1 Safety Review  
If the halting rule (see Section 9.5) is met, a safety summary report (SSR) will be produced and 
sent to the SMC.  The content and format of the SSR will be defined in the SMC charter.  
11.4 Final Analysis Plan  
11.4.1 Physiological Measures 
A shift table describing change from baseline at the  48 hour post- dose time point will be 
provided for liver function tests, magnesium and serum creatinine. 
11.4.2 Pharmacokinetic Analysis and Assessment of Pharmacokinetic -
Pharmacodynamic Target Attainment  
The methodology used to conduct the PK and PK- PD target attainment analyses will be 
described in detail in a formal SAP and is briefly outlined in the sections below. 
Initial Exploratory Analysis. Box and whisker plots will be used to explore the potential for 
any outliers in the observed concentration- time dat aset. Queries will be generated to resolve 
potential erroneous time or concentration data point entries due to transcription or measurement errors. Individual concentration-time plots presented on both a linear and semi -log scale will be 
visualized to ascertain the general structure that may best model the population profile. 
Non-compartmental pharmacokinetic analysis.  Non -compartmental analysis (NCA) will 
serve as the initial approach to generate base PK parameter estimates for both the free and total 
minocycline concentration -time data. An appropriate statistical analysis software package such 
as R will be used to execute the NCA.  This descriptive analysis will permit direct comparisons of 
the PK data generated from the present study to those generated th rough studies conducted 
several decades ago.   The following PK parameters will be calculated: maximum plasma 
concentration (C max), plasma concentration at 24 hours after a dose (C 24), time to  Cmax (Tmax), 
area under the curve from time zero to 12 hours (AUC 0–12), 24 hours (AUC 0–24), the last 
quantifiable sample (AUC 0–last) and infinity (AUC 0–∞). Actual infusion and sampling times will 
be used in the calculation of the PK parameters.    
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
47 Population Pharmacokinetic Analysis. Population pharmacokinetic analysis provides a 
platform to identify patient covariates which can help explain a portion of the interindividual 
variability in selected PK parameters. The non- linear mixed effects modeling software 
NONMEM Version 7.3 (ICON Development Solutions, Ellicott City, MD) will be used to 
develop the population PK model for both free and total minocycline concentrations in plasma. The first -order conditional estimation method with interaction (FOCEI) will be utilized; other 
estimation methods such as expectation -maximiza tion (e.g., SAEM) will also be considered. 
The initial approach for development of a base structural model will be to co-model the free and total plasma minocycline concentration -time data, assuming both can be adequately 
characterized using a linear two -compartment model with zero -order infusion as has been used 
previously.
12 Other model modifications will be considered as necessary.  Upon selection of an 
appropriate base structural PK model, patient covariate effects will be evaluated using stepwise forwa rd selection (α=0.01) followed by stepwise backward elimination (α=0.001) processes.  
Monte Carlo Simulation 
Using the final population PK model including all statistically significant covariate effects, 
Monte Carlo simulation will be performed to generate plasma minocycline concentration time data in a virtual population of critically ill patients with gram negative infections. Minocycline 
doses of 200 mg given as a 1-hour IV infusion, will be evaluated. The total drug and free- drug 
area under the plasma mi nocycline concentration- time curve values will then be calculated for 
each simulated patient using numerical integration. As a quality -control check, the simulated 
median and 90% prediction interval will be overlaid upon the observed plasma minocycline concentration -time data from critically -ill patients in this study where applicable to ensure the 
simulated data agree with the observed data.   
Pharmacokinetic -Pharmacodynamic Target Attainment Assessment  
The PK -PD index associated with the antimicrobial eff icacy of minocycline and other 
tetracy clines against A. baumannii  is known to be free- drug AUC:MIC ratio ( fAUC:MIC). The 
minocycline fAUC:MIC ratios which resulted in bacterial stasis and 1 -log change in log
10CFU 
was on average approximately 12 and 18 across four different clinical isolates of A. baumannii  
studied in a rat lung pneumonia infection model.13 
The percent of simulated patients achieving the fAUC:MIC target of either 12 or 18 will 
minimally be evalu ated for the FDA approved IV minocycline dosing regimen  of 200 mg 
simulated and assessed over a range of MIC values for A. baumannii. Recent surveillance MIC 
data will be obtained to assess whether the PK- PD target attainment is adequate for the majority 
of the observed MIC distribution for A. baumannii.  
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
48 12 SOURCE DOCUMENTS AND  ACCESS TO SOURCE 
DATA/DOCUMENTS 
Each participating site will maintain appropriate medical and research records for this trial, in 
compliance with ICH E6, Section 4.9 and regulatory and institutional requirements for the protection of confidentiality of subjects.  Each site will permit authorized representatives of the 
DMID, its designees, and appropriate regulatory agencies to examine (and when required by 
applicable law, to copy) clini cal records for the purposes of quality assurance reviews, audits, 
and evaluation of the study safety and progress.  These representatives will be permitted access to all source data, which include, but are not limited to, hospital records, clinical and of fice 
charts, laboratory notes, memoranda, evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions certified after verification as being accurate and complete, microfiches, photographic negative s, microfilm or magnetic media, 
x-rays, and subject files and records kept at the pharmacy, at the laboratories, and medico-technical departments involved in the clinical trial.  Data collection forms will be derived from the eCRFs and be provided by the S tatistical and Data Coordinating Center (SDCC).  
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
49 13 QUALITY CONTROL AND QUALITY ASSURANCE  
Following a written DMID -accepted protocol- specific quality management plan, each 
participating site is responsible for conducting routine quality assurance (QA) and quality control 
(QC) activities to internally monitor study progress and protocol compliance. Each  site principal 
investigator will provide direct access to all trial- related source data/data collection forms, 
reports and training documentation for the purpose of monitoring and auditing by the sponsor, 
and inspection by local and regulatory authorities. The site principal investigator will ensure all study personnel are appropriately trained and current applicable documentations are maintained 
on site.  
The SDCC will implement quality control procedures beginning with the data entry system and 
generate data quality control checks that will be run on the database. Any missing data or data 
anomalies will be communicated to the site(s) for clarification and resolution.  
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
50 14 ETHICS/PROTECTION OF  HUMAN SUBJECTS  
14.1 Ethical Standard  
The investigator will ensure that this study is conducted in full conformity with the principles set 
forth in The Belmont Report: Ethical Principles and Guidelines for the Protection of Human 
Subjects of Research of the US National Commission for the Protection of Human Subjects of 
Biomedical and Behavioral Research (April 18, 1979) and codified in 45 CFR Part 46 and/or the ICH E6; 62 Federal Regulations 25691 (1997).   
14.2 Institutional Review Board  
Prior to enrollment of subjects into this trial, the approved protocol and informed consent form will be reviewed and approved by the appropriate IRB listed on its Federal  Wide Assurance 
(FWA ). The responsible official for the IRB will sign the IRB letter of approval of the protocol 
prior to the start of this trial and a copy will be provided to DMID. The IRB FWA number will 
be provided to DMID. 
Should amendments to the protocol be required, the amendments will be approved by the 
sponsor and provided to the site principal investigator for submission to the IRB. 
14.3 Informed Consent Process  
Informed consent is a process that is initiated prior to the individual’s agreeing to part icipate in 
the study and continuing throughout the individual’s study participation.  Extensive discussion of 
risks and possible benefits of this therapy will be provided to the subject/LAR.  Consent forms 
describing in detail the study interventions/products, study procedures, and risks are given to the subject/LAR and written documentation of informed consent is required prior to starting intervention/administering study product.  Consent forms will be IRB-approved and the 
subject/LAR will be asked to rea d and review the document. Upon reviewing the document, the 
investigator will explain the research study to the subject/LAR and answer any questions that 
may arise.  The subject/LAR will sign the informed consent document prior to any procedures being done specifically for the study.  The subject/LAR should have the opportunity to discuss 
the study with their surrogates or think about it prior to agreeing to participate.  The subject/LAR 
may withdraw consent at any time throughout the course of the trial.  A copy of the informed consent document will be given to the subject/LAR for their records.  The rights and welfare of 
the subjects will be protected by emphasizing to them that the quality of their medical care will 
not be adversely affected if they decli ne to participate in this study.  
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
51 14.4 Exclusion of Women, Minorities, and Children (Special Populations)  
This study will enroll individuals who are receiving care in an ICU. The target population will be 
adults including all minorities. This is the first time this product is being tested in this critically ill population, and as such, pregnant women and children will not be able to be included. 
14.5 Subject Confidentiality  
Subjects will have code numbers and will not be identified by name. Subject confidentiality is strictly held in trust by the participating investigators, their staff, and the sponsor(s) and their 
agents.  This confidentiality is extended to cover testing of biological samples and the clinical 
information relating to participating subjects.  
The study protocol, documentation, data, and all other information generated will be held in 
strict confidence.  No information concerning the study or the data will be released to any 
unauthorized third party without prior written approval of the sponsor. 
All info rmation provided by the Sponsor and all data and information generated by the 
participating sites as part of this trial (other than a subject’s medical records) will be kept 
confidential by the site principal investigator and other study personnel to the e xtent permitted by 
law. This information and data will not be used by the site principal investigator or other study 
personnel for any purpose other than conducting this trial. These restrictions do not apply to: (1) 
information which becomes publicly available through no fault of the site principal investigator 
or other study personnel; (2) information which is necessary to disclose in confidence to an IRB solely for the evaluation of this trial (3) information which is necessary to disclose in order to provide appropriate medical care to a study subject; or (4) study results which may be published 
as described in Section 16. If a written contract for the conduct of this trial which includes 
confidentiality provisions inconsistent with this statement is executed, that contract’s 
confidentiality provisions shall apply rather than this statement. 
The study monitor or other authorized representatives of the sponsor may inspect all documents 
and records required to be maintained by the investigator, including but not limited to, medical records (office, clinic, or hospital) and pharmacy records for the subjects in this study.  The clinical study site will permit access to  such records.  
14.6 Study Discontinuation  
If the trial is discontinued, subjects who sign the informed consent form, and who receive study 
drug will continue to be followed for safety, as per the schedule of events.  
14.7 Future Use of Stored Specimens  
No samples wi ll be retained for future testing purposes.   
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
52 15 DATA HANDLING AND RE CORD KEEPING  
The investigator is responsible to ensure the accuracy, completeness, legibility, and timeliness of 
the data reported  
Data collection forms will be derived from the eCRFs and provided by the SDCC to the sites to 
record and maintain data for each subject enrolled i n the study.  All source documents should be 
completed in a neat, legible manner to ensure accurate interpretation of data.  Permanent ink is required to ensure clarity of reproduced copies.  When making a change or correction, the 
original entry should be crossed out with a single line, and the change should be initialed and 
dated.  Do not erase, overwrite, or use correction fluid or tape on the original.  
Data reported in the eCRF should be consistent with the data collection form/source documents 
or the discrepancies should be documented.   
15.1 Data Management Responsibilities  
All source documents and laboratory reports must be reviewed by the clinical team and data 
entry staff, who will ensure that they are accurate and complete.  Adverse events must be graded, 
assessed for severity and causality, and reviewed by the site PI or designee.  
Data collection is the responsibility of the clinical trial staff at the site under th e supervision of 
the site PI.  During the study, the investigator must maintain complete and accurate documentation for the study. 
The Emmes  Corporation will serve as the Statistical and Data Coordinating Center for this study 
and will be responsible for data management, quality review, analysis, and reporting of the study 
data.  
15.2 Data Capture Methods 
Clinical data (including SAEs and concomitant medications data) and clinical laboratory data 
will be entered into a 21 CFR Part 11- compliant Internet Data Entry  System (IDES) provided by 
The Emmes Corporation.  The data system includes password protection and internal quality checks, such as automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate.  Clinical data will be entered directly from the data collection forms completed by the 
study personnel.  
15.3 Types of Data  
Data for this study will include safety and laboratory (pharmacokinetic) data. 
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
53 15.4 Timing/Reports  
A final report will be prepared following the availability of all the c linical, safety, and 
pharmacokinetic data. Safety data will be provided to the SMC and investigators as per the SMC 
charter.  
15.5 Study Records Retention  
Study documents should be retained for a minimum of 2 years after the last approval of a marketing applica tion in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or at least 2 years have elapsed since the formal discontinuation of clinical development of the investigational product.  These documents should be retained for a longer period, however, if required by local regulations.  No records will be destroyed without 
the written consent of the sponsor, if applicable.  It is the responsibility of the sponsor to inform 
the investigator when these documents no longer need to be retained . 
15.6 Protocol Deviations 
A protocol deviation is any noncompliance with the clinical trial protocol, Good Clinical Practice (GCP), or Manual of Procedures requirements.  The noncompliance may be either on the part of the subject, the investigator, or the study site staff.  As a result of deviations, corrective actions 
are to be developed by the site and implemented promptly.  
These practices are consistent with ICH E6:  
4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3 
5.1 Quality Assurance and Quality Control, section 5.1.1 
5.20 Noncompliance, sections 5.20.1, and 5.20.2. 
It is the responsibility of the site to use continuous vigilance to identify and report deviations 
within 5 working days of identification of the protocol deviation, or within 5 working days of the 
scheduled protocol-required activity.  All deviations must be promptly reported to DMID, via 
The Emmes Corporation’s IDES.  
All deviations from the protocol must be addressed in study subject source documents.  A 
completed copy of the DMID Protocol Deviation Form ( IDES form) must be maintained in the 
regulatory file, as well as in the subject’s source document.  Protocol deviations must be sent to 
the local IRB per their guidelines.  The site PI/study staff is re sponsible for knowing and 
adhering to their IRB requirements.  
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
54 16 PUBLICATION POLICY  
Following completion of the study, the investigator is expected to publish the results of this 
research in a scientific journal.  All investigators funded by the NIH must submit or have 
submitted them to the National Library of Medicine’s PubMed Central an electronic version of 
their final, peer-reviewed manuscripts upon acceptance for publication, to be made publically available no later than 12 months after the official date of publication.  The NIH Public Access 
Policy ensures that the public has access to the published results of NIH funded research.  It 
requires investigator to submit final peer-reviewed journal manuscripts that arise from NIH funds to the digital archive PubMed Central upon acceptance for publication. Further, the policy stipulates that these papers must be accessible to the public on PubMed Central no later than 12 
months after publication. 
The International Committee
 of Medical Journal Editors (ICMJE) member journals have adopted 
a trials -registration policy as a condition for publication. This policy requires that all clinical 
trials be registered in a public trials registry such as ClinicalTrials.gov*, which is sponsored by 
the National Library of Medicine.  Other biomedical journals are considering adopting similar policies.  It is the responsibility of DMID to register this trial in an acceptable registry.  Any clinical trial starting enrollment after 01 July 2005 must be registered on or before subject 
enrollment.  For trials that began enrollment prior to this date, the ICMJE member journals will require registration by 13 September 2005, before considering the results of the trial for publication. 
The ICMJE defines a clinical trial as any research  project that prospectively assigns human 
subjects to intervention or comparison groups to study the cause- and-effect relationship between 
a medical intervention and a health outcome.  While studies designed for other purposes, such as 
to study pharmacokinetics or major toxicity (e.g., Phase I trials), are exempt from this policy, a 
separate NIH policy requires the registration and reporting in ClinicalTrials.gov for all trials 
receiving NIH funding for studies starting as of January 18, 2017. 
All publications resulting from this study will be reviewed by DMID prior to submittal for 
publication.  All presentations, abstracts, or manuscripts will be reviewed by DMID prior to 
submission or presentation. 
NIH contract support will be acknowledged in all publications. 
*Journal Citation:  
De Angelis C , Drazen JM, Frizelle FA , Haug C , Hoey J , Horton R , et al. Clinical trial registration: a statement from 
the International Committee of Medical Journal Editors. N Engl J Med. 2004;351:1250 -1. 
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
55 17 LITERATURE REFERENC ES 
1. Adibhesami H, Douraghi M, Rahbar M, Abdollahi A. Minocycline activity against clinical 
isolates of multidrug -resistant Acinetobacter baumannii: Clin Microbiol Infect. 2015 
Nov;21(11):e79-80. doi: 10.1016/j.cmi.2015.07.007. Epub 2015 Jul 18. 
2. Goff DA, Kaye KS. Minocycline: an old drug for a new bug: multidrug- resistant 
Acinetobacter baumannii. Clin Infect Dis 2014;1. 
3. Ritchie DJ, Garavaglia -Wilson A. A review of intravenous minocycline for treatment of 
multidrug -resistant Acinetob acter infections. Clin Infect Dis 2014;1. 
4. Chmielarczyk A, Pilarczyk -Zurek M, Kaminska W, et al. Molecular Epidemiology and Drug 
Resistance of Acinetobacter baumannii Isolated from Hospitals in Southern Poland: ICU as a 
Risk Factor for XDR Strains. Microb Drug Resist 2016;8:8. 
5. Gao F, Ye Q, Wan Q, Liu S, Zhou J. Distribution and resistance of pathogens in liver 
transplant recipients with Acinetobacter baumannii infection. Ther Clin Risk Manag 2015;11:501-5. 
6. Kempf M, Rolain JM. Emergence of resis tance to carbapenems in Acinetobacter baumannii 
in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents 2012;39:105-14. 
7. Nie XM, Huang PH, Ye QF, Wan QQ. The Distribution, Drug Resistance, and Clinical 
Characteristics of Acinetobacter  baumannii Infections in Solid Organ Transplant Recipients. 
Transplant Proc 2015;47:2860-4. 
8. Viehman JA, Nguyen MH, Doi Y. Treatment options for carbapenem- resistant and 
extensively drug -resistant Acinetobacter baumannii infections. Drugs 2014;74:1315-33. 
9. Shields RK, Clancy CJ, Gillis LM, et al. Epidemiology, clinical characteristics and 
outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ 
transplant recipients. PLoS ONE 2012;7:20. 
10. MedCo. Investigator Brochure - Minocin (minocycline) for Injection. In: Company TM, ed. 
Parsippany, NJ; 2016. 
11. Julious SA, Owen RJ. A comparison of methods for sample size estimation for non-
inferiority studies with binary outcomes. Stat Methods Med Res 2011;20:595-612. 
 
 
ACUMIN   Version 3.0 
 19 November, 2018  
 
 
56 SUPPL EMENTS/APPENDICES  
 
 
   
ACUMIN                  Version 3.0  
     19 November 2018  
57 
 APPENDIX A: SCHEDULE  OF EVENTS  
Table 1: Schedule of Events  
 
 
 
  
 
   
 
  
 
   
 
  
Screening1 Baseline  
(Hr. 0)  
 
 Study Visits (post start of infusion) 17 Supplemental 
Visit  (as 
needed )18 
 
 1 hr. 4 hrs.  12 hrs.  24 hrs.  36 hrs.  48 hrs.  
Study windows  - -30 min  +0.5 hr.  +1 hr.  ± 2 hrs.  ± 2 hrs.  ± 2 hrs.  ± 2 hrs.  - 
Clinical Evaluations  
Informed consent  
 X         
Medical History & Demographics  X         
Height 2 X1         
Weight 2  X16    X  X  
Inclusion / Exclusion Criteria  X         
Targeted Physical Examination 3 X        X 
Vital signs 4  X X16 X   X  X X 
Collection of RRT’s being received    X X X X X X  
Concomitant Medications 5 X X X X X X X X X 
Collection of SAEs  6  X X X X X X19 X19 X19 
Laboratory Evaluations  
Blood chemistry 7   
5 mL1 
 X14         
 
 
 Liver function tests 8  X14       
5 mL  
  
Serum creatinine 9  5 mL15 5 mL  5 mL  5 mL  5 mL  5 mL   
Magnesium       
Hematology10   2 mL1 2 mL14    2 mL  2 mL  
Serum hCG Pregnancy Test 11 5 mL1         
Urinalysis 12 X1         
PK Blood Collection  13  6 mL15 6 mL 6 mL 6 mL 6 mL 6 mL 6 mL  
Study Drug  
Study Drug Administration   X        
APPROXIMATE TOTAL BLOOD 
  12 mL 13 mL 11 mL 11 mL 11 mL 13 mL 11 mL 13 mL  
ACUMIN                  Version 3.0  
     19 November 2018  
58 
  
 
Footnotes 
1. Screening evaluations should be completed within 48 hours prior to enrollment , with exception to  the following procedures:  
- Height can be pulled from the medical records associated with the current hospital admission OR collected within the screening window.  
- Clinical laboratory evaluations  obtained for clinical care purposes (standard of care results) within 48hrs of screening are acceptable for screening. A pregnancy test 
at any time during the current hospitalization is acceptable for screening.  
2. Height  and weight  will be measured or calculated as per instructions in the Manual of Procedures, rather than estimated or by report of relative.   
3. A tar geted physical examination should include an examination of specific systems, to be guided by symptomatology.  
4. Vital signs should include systolic  and diastolic blood pressure (mm Hg), heart rate (HR), respiratory rate, and temperature.  
5. Concomitant medications should be collected from 24 hours prior to start of infusion through 48 hours post  start of  infusion, as well as  SAE follow -up visit as needed  
6. SAEs should be collected from start of infusion through 24 hours post  start of  infusion.  
7. Blood chemistry panel should include: potassium, sodium, chloride, bicarbonat e, glucose, blood urea nitrogen.   
8. Liver function tests should include: AST, ALT, alkaline phosphatase, albumin, total bilirubin.  
9. Serum creatinine may be run as part of the blood chemistry panel if preferred.  
10. Hematology should include: hemoglobin, hematocrit, white blood cell count [WBC], WBC differential, red blood cell count, platelets.  
11. Serum hCG pregnancy test is only required for females of child- bearing potential. 
12. Urinalysis should include: p rotein, glucose, ketones, bilirubin, blood, nitrites, LCE, urobilinogen, specific gravity, and pH . 
13. Refer to the Manual  of Procedures  for further details.  
14. A hematology panel, c hemistry panel and liver function tests should be repeated if not collected withi n 8 hours prior to  the start of study drug infusion 
15. The Baseline serum creatinine, magnesium and Bas eline PK blood draw must  be drawn just prior to  the start of  study drug  infusion.  
16. The B aseline w eight  and vital signs  should be  collected  as close to the st art of study drug infusion  as possible.  
17. Study windows are as described in the table.  For example: 1hr time point with a window of +0.5 hrs, the PK sample can be dra wn from 1 to 1.5 hours post start of 
infusion.  At the 24 hour time point, the window is ± 2 hours, so the PK sample can be drawn from 22 to 26 hours post start of infusion.  
ACUMIN                  Version 3.0  
     19 November 2018  
59 
 18. Supplemental  visits should be conducted at the Investigator’s discretion and include  follow up on any SAEs that are considered related to Study Drug, as well as 
unscheduled visits . Please see protocol  Section 7.6 for details on the SAE Follow -up V isit procedures  and Section 7.8 for details on Unscheduled V isits.  
19. SAEs follow -up only after 24 hours  